NSETrading Window26 Jun 2026 · 26 Jun 2026, 05:06 pm
Trading Window
Orchid Pharma Limited · ORCHPHARMA
✦ AI SummaryResults
Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk3/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Attachments (1)
📄pdf
Download →
ORCHPHARMA_26062026170426_Stx_ltr_windowclosure_sgn.pdf
View document text
June 26, 2026
National Stock Exchange of India Limited, BSE Limited
Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers
Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001
Symbol: ORCHPHARMA Scrip Code: 524372
Ref: (i) Securities and Exchange Board of India (Prohibition of Insider Trading)
Regulations, 2015, as amended, read with the Code of Conduct to
regulate, monitor and report trading by Insiders of Orchid Pharma
Limited “the Company”)
(ii) SEBI Circular no. SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated
July 19, 2023
Sub: Intimation of Trading Window Closure for the Quarter-I of Financial Year
2026-27, ending on June 30, 2026
Dear Sir/Madam,
With reference to the captioned subject and pursuant to Securities and Exchange Board
of India (Prohibition of Insider Trading) Regulations, 2015 (‘PIT Regulations’), as
amended, read with the Company’s Code of Conduct to regulate, monitor and report
trading by Insiders, it is hereby intimated that Trading Window for trading in Securities
of the Company shall remain closed from July 01, 2026 (‘Trading Window Closure
commencement date’) till the date on which 48 hours ends (‘Trading Window Closure
end date’) after declaration of Unaudited Limited Reviewed Financial Results
(Standalone and Consolidated) of the Company for the Quarter-I of Financial Year 2026-
27, ending on June 30, 2026 (‘Trading Window Closure Period’).
The date of meeting of the Board of Directors of the Company, inter-alia, to consider
and approve the Unaudited Limited Reviewed Financial Results (Standalone and
Consolidated) for the Quarter-I of Financial Year 2026-27, ending on June 30, 2026 will
be intimated separately in due course.
Accordingly, all persons to whom the Company’s Code of Conduct to regulate, monitor
and report trading by Insiders is applicable and the persons, to whom the said code is
not applicable but are in possession of Unpublished Price Sensitive Information of the
Company, are hereby intimated not to trade in the Securities of the Company during
the said Trading Window Closure Period.
We request you to take the above intimation on records.
Thanking You,
For Orchid Pharma Limited
Kapil Dayya
Company Secretary & Compliance Officer
Membership No.: F10698
Orchid Pharma Limited Regd. Office: Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Dist.- 603110, Tamil Nadu, India
Phone: (91)-44- 2744 4471/72/73 Email: Corporate@orchidpharma.com Website: www.orchidpharma.com CIN: L24222TN1992PLC022994